Tag: xen gel stent

Allergan’s leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. Presentations will include updated analyses that help further scientific understanding of DURYSTA® (bimatoprost intracameral implant), as well as new data on the XEN® Gel Stent. The DURYSTA data presentations coincide with the two-year anniversary of the U.S. Food and Drug Administration (FDA) approval of this first-of-its-kind eye pressure lowering treatment for glaucoma patients in March 2020.

A lot happened last year!  Let's recap a few highlights: FDA Approvals: BromSite Corneal Cross-linking // (20/20 Glance rundown) Cypass // (20/20 Glance rundown) Raindrop corneal inlay // (20/20 Glance rundown) ReSTOR Multifocal Toric IOL Tecnis...